News / Presse
HAPILA brings API manufacturing solutions to Chemspec Europe 2022
08 July 2022
High-potency active ingredient specialist CDMO HAPILA GmbH (HAPILA) made a highly successful showing at the recently reconvened physical Chemspec Europe trade show in Frankfurt.
HAPILA has been a consistent presence at Chemspec since 2015 and was again an exhibitor this year, as a featured partner on a stand jointly shared with other German companies active in the API and Fine Chemical fields.
Meeting supply needs
The HAPILA team at Chemspec was led by CEO Dr. Uwe Müller, who reports that more severe supply chain problems in the wake of the Covid pandemic has increased interest in finding reliable CMOs to undertake multistep chemical synthesis and GMP-manufacturing.
“Some pharmaceutical companies are looking for European and particularly German partners to fulfill all work related to high potency APIs to solve their technical and capacity problems,” said Dr. Müller.
“In this regard, we were able to have many very interesting conversations based on our long experience and advanced facilities,” he added.
HAPILA was active in networking across the Chemspec show, with offers that highlighted the company’s advanced technical abilities in small molecule development and manufacturing, along with high degree of flexibility and responsiveness in solving specific customer problems.
“It was my impression that many senior pharma professionals came to Chemspec 2022 looking to find an experienced and reliable partner to solve their development and GMP manufacturing API-issues and quite a few of them were plainly impressed with what we can offer,” said Dr. Müller .
“They brought us interesting challenges and already we were able to suggest promising approaches,” he reported.